Oral and topical finasteride in the treatment of male androgenetic alopecia – narrative review
Abstract
Background
Androgenetic alopecia is the most common form of progressive non scarring hair loss in men and is driven by dihydrotestosterone mediated miniaturization of hair follicles. The condition may negatively affect psychological well being and quality of life. Finasteride, a 5 alpha reductase inhibitor, is a key pharmacologic therapy.
Aims
To evaluate the mechanism of action, metabolism, efficacy, and safety of finasteride in male androgenetic alopecia, with comparison of oral and topical formulations, assessment of systemic exposure and DHT reduction, and review of adverse effects, alternative FDA approved treatments, combination strategies, and broader clinical relevance.
Methods
A narrative review was conducted using PubMed and Google Scholar for English language studies published between 2015 and 2026. Fifty one references were included. Priority was given to randomized controlled trials, systematic reviews, meta analyses, pharmacokinetic studies, and pharmacovigilance reports. Data were synthesized descriptively without formal quality assessment or meta analytic pooling.
Results
Finasteride inhibits type II and III 5 alpha reductase, lowering scalp and serum DHT levels and stabilizing hair growth. Oral finasteride 1 mg daily significantly improved hair count and density, with reported increases of 18.37 hairs per cm² in comparative analyses. Topical 0.25 percent formulations showed comparable efficacy after 24 weeks with markedly lower systemic exposure and smaller…
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.